Should combination chemotherapy serve as the backbone in clinical trials of advanced pancreatic cancer?: A pooled analysis of phase II trials of gemcitabine-containing doublets plus bevacizumab
- Citation:
- Pancreas vol 43 (3) 343-349
- Year:
- 2014
- Type:
- Manuscript
- Funding:
- NCTN
- Endpoint:
- Secondary-not-in-original
- Analysis:
- Primary
- Data Sharing:
- No-Data-Sharing
- Status:
- Presented/Published
- Citation Status:
- pmc-release
- Note:
- Methodological:
- No
- Biospecimen:
- No
- SDC:
- No
- Book Volume:
- Parents:
- 546
- Children:
- None
- Pharmas:
- Grants:
- U10CA180821 , U10 CA035267, U10 CA052352, CA-374-4, N01 CA035431, CA-52352, CA-63844, CA-35195, U10 CA180821, CA-7417, U10 CA035448, U10 CA035195, CA-35103, CA-25224, N01 CA063844, CA-35113, U10 CA035101, U10 CA035113, U10 CA035415, U10 CA063849, CA-35415, U10 CA035431, CA-35448, CA-35101, U10 CA025224, CA-35267, U10 CA063844, CA-63849, UL1 TR000371, U10 CA035103
- Corr. Author:
- Authors:
- Katherine Van Loon Anne M. Espinoza David R. Fogelman Robert A. Wolff Milind M. Javle Renuka V. Iyer Vincent J. Picozzi Ludmila Katherine Martin Tanios Bekaii-Saab Margaret A. Tempero Nathan R. Foster George P. Kim Andrew H. Ko
- Networks:
- Study
- NCCTG-N034A
- Multiple Studies, or Legacy Studies in Alliance Study:
- Phases:
- 2
- Keywords:
- pancreatic cancer, gemcitabine, clinical trial design, pooled analysis